GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (NAS:ACST) » Definitions » Net Cash per Share

Acasti Pharma (Acasti Pharma) Net Cash per Share : $1.45 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Acasti Pharma's Net Cash per Share for the quarter that ended in Dec. 2023 was $1.45.

The historical rank and industry rank for Acasti Pharma's Net Cash per Share or its related term are showing as below:

ACST' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.23   Med: 2.99   Max: 102.85
Current: 1.85

During the past 13 years, the highest Price-to-Net-Cash Ratio of Acasti Pharma was 102.85. The lowest was 1.23. And the median was 2.99.

ACST's Price-to-Net-Cash is ranked better than
71.86% of 867 companies
in the Biotechnology industry
Industry Median: 3.92 vs ACST: 1.85

Acasti Pharma Net Cash per Share Historical Data

The historical data trend for Acasti Pharma's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acasti Pharma Net Cash per Share Chart

Acasti Pharma Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 2.33 12.42 3.16 2.25

Acasti Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.50 2.25 1.70 1.65 1.45

Competitive Comparison of Acasti Pharma's Net Cash per Share

For the Biotechnology subindustry, Acasti Pharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acasti Pharma's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acasti Pharma's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Acasti Pharma's Price-to-Net-Cash falls into.



Acasti Pharma Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Acasti Pharma's Net Cash per Share for the fiscal year that ended in Mar. 2023 is calculated as

Net Cash per Share (A: Mar. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(27.89-11.168-0)/7.43547
=2.25

Acasti Pharma's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(25.114-11.505-0)/9.3994
=1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acasti Pharma  (NAS:ACST) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Acasti Pharma Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Acasti Pharma (Acasti Pharma) Business Description

Traded in Other Exchanges
Address
3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
Executives
George Kottayil director 49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540
A Brian Davis director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Edward Neugeboren director 282 NEW NORWALK ROAD, NEW CANAAN CT 06840
Vimal Kavuru director 11 MAACKA DRIVE, HOLMDEL NJ 07733
Donald Olds director 545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3
Amresh Kumar officer: VP Program Management 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Carrie D'andrea officer: VP Clinical Operations 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Prashant Kohli officer: Chief Executive Officer 206 CAMBRIDGE LANE, NEWTOWN PA 13940
R. Loch Macdonald officer: Chief Medical Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Michael Derby director 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
William A Haseltine director
Rajitha Grace 2018 Irrevocable Trust 10 percent owner 40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753
Swami Sambamurty Iyer 10 percent owner 20 TULSA COURT, MONMOUTH JUNCTION NJ 08852
Brian D. Ford officer: CHIEF FINANCIAL OFFICER 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
John Canan director C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202